157 related articles for article (PubMed ID: 28592757)
1. [HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy].
Kobayashi H; Miyagi N
Rinsho Ketsueki; 2017; 58(5):443-448. PubMed ID: 28592757
[TBL] [Abstract][Full Text] [Related]
2. Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Fedele PL; Gregory GP; Gilbertson M; Shortt J; Kumar B; Opat S; Grigoriadis G
Ann Hematol; 2016 Mar; 95(4):667-8. PubMed ID: 26801792
[No Abstract] [Full Text] [Related]
3. Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
Dittus C; Grover N; Ellsworth S; Tan X; Park SI
Leuk Lymphoma; 2018 Sep; 59(9):2121-2127. PubMed ID: 29303024
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Castillo JJ; Guerrero-Garcia T; Baldini F; Tchernonog E; Cartron G; Ninkovic S; Cwynarski K; Dierickx D; Tousseyn T; Lansigan F; Linnik Y; Mogollon R; Navarro JT; Olszewski AJ; Reagan JL; Fedele P; Gilbertson M; Grigoriadis G; Bibas M
Br J Haematol; 2019 Feb; 184(4):679-682. PubMed ID: 29527667
[No Abstract] [Full Text] [Related]
5. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
Arora N; Gupta A; Sadeghi N
BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993364
[TBL] [Abstract][Full Text] [Related]
6. [Long-term complete remission of HIV-negative primary testicular plasmablastic lymphoma treated with bortezomib in combination with EPOCH].
Fujishima T; Kawabata Y; Michishita Y; Kitabayashi A; Takahashi N
Rinsho Ketsueki; 2022; 63(10):1386-1391. PubMed ID: 36351644
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
[TBL] [Abstract][Full Text] [Related]
8. Testicular Plasmablastic Lymphoma in an HIV-Negative Patient: A Rare Case Presentation.
Nwanwene K; Khan NAJ; Alsharedi M
J Investig Med High Impact Case Rep; 2021; 9():23247096211017423. PubMed ID: 34032157
[TBL] [Abstract][Full Text] [Related]
9. Incorporating Bortezomib in the Management of Plasmablastic Lymphoma.
Umeanaeto O; Gamboa J; Diaz J; Hakim MN; Corral J; Philipovskiy A; Gaur S
Anticancer Res; 2019 Sep; 39(9):5003-5007. PubMed ID: 31519607
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-contained chemotherapy and thalidomide combined with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) play promising roles in plasmablastic lymphoma: a case report and literature review.
Cao C; Liu T; Zhu H; Wang L; Kai S; Xiang B
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e145-50. PubMed ID: 25225082
[No Abstract] [Full Text] [Related]
11. Plasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settings.
Yanamandra U; Sahu KK; Jain N; Prakash G; Saikia U; Malhotra P
Ann Hematol; 2016 Oct; 95(10):1715-7. PubMed ID: 27324386
[No Abstract] [Full Text] [Related]
12. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma.
Castillo JJ; Reagan JL; Sikov WM; Winer ES
Br J Haematol; 2015 May; 169(3):352-5. PubMed ID: 25612847
[TBL] [Abstract][Full Text] [Related]
13. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG
Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556
[TBL] [Abstract][Full Text] [Related]
14. [Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
Gui L; He XH; Liu P; Yang JL; Qin Y; Zhou SY; Yang S; Zhang CG; Shi YK
Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):762-767. PubMed ID: 27719718
[TBL] [Abstract][Full Text] [Related]
15. [Isolated plasmablastic lymphoma of nasal mucosa in an immunocompetent patient achieving complete remission after multimodal treatment: about an African patient and literature review].
Tissir R; Rais H; Tazi I
Pan Afr Med J; 2020; 37():22. PubMed ID: 33062124
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
Koizumi Y; Uehira T; Ota Y; Ogawa Y; Yajima K; Tanuma J; Yotsumoto M; Hagiwara S; Ikegaya S; Watanabe D; Minamiguchi H; Hodohara K; Murotani K; Mikamo H; Wada H; Ajisawa A; Shirasaka T; Nagai H; Kodama Y; Hishima T; Mochizuki M; Katano H; Okada S
Int J Hematol; 2016 Dec; 104(6):669-681. PubMed ID: 27604616
[TBL] [Abstract][Full Text] [Related]
18. Solitary plasmablastic lymphoma in the esophagus.
Mihara K; Sasaki N; Mamoru O; Kanbe M; Ichinohe T; Suehiro S
Ann Hematol; 2016 Apr; 95(5):845-6. PubMed ID: 26925582
[No Abstract] [Full Text] [Related]
19. Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.
Marrero WD; Cruz-Chacón A; Castillo C; Cabanillas F
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e275-e277. PubMed ID: 29753690
[No Abstract] [Full Text] [Related]
20. Primary Maxillary Sinus Plasmablastic Lymphoma in HIV/AIDS.
Basavaraj A; Kadam M; Kadam DB
J Assoc Physicians India; 2016 May; 64(5):71-72. PubMed ID: 27735156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]